RVX 25
Alternative Names: RVX-25Latest Information Update: 17 Mar 2025
At a glance
- Originator ROCKETVAX
- Class Attenuated vaccines; Synthetic vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Middle East respiratory syndrome coronavirus
Most Recent Events
- 13 Mar 2025 Preclinical trials in Middle East respiratory syndrome coronavirus (Prevention) in Switzerland (Intranasal), prior to March 2025 (ROCKETVAX pipeline, March 2025)
- 03 Mar 2021 ROCKETVAX has patents pending for Fully synthetic, long-chain nucleic acid for vaccine production to protect against coronaviruses worldwide